D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 107 Citations 56,085 594 World Ranking 2796 National Ranking 64

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Antonio Palumbo mostly deals with Multiple myeloma, Internal medicine, Surgery, Bortezomib and Thalidomide. His studies deal with areas such as Clinical trial, Transplantation and Hazard ratio as well as Multiple myeloma. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.

His study in Surgery is interdisciplinary in nature, drawing from both Adverse effect and Dexamethasone. His research integrates issues of Proteasome inhibitor and Urology in his study of Bortezomib. Antonio Palumbo combines subjects such as Warfarin and Intention-to-treat analysis with his study of Thalidomide.

His most cited work include:

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (1547 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Multiple myeloma, Internal medicine, Surgery, Lenalidomide and Oncology. His study on Multiple myeloma is covered under Immunology. In his research, Progressive disease is intimately related to Gastroenterology, which falls under the overarching field of Internal medicine.

His study ties his expertise on Adverse effect together with the subject of Surgery. The concepts of his Lenalidomide study are interwoven with issues in Progression-free survival, Newly diagnosed, Maintenance therapy, Intensive care medicine and Hazard ratio. The various areas that Antonio Palumbo examines in his Oncology study include Relapsed refractory, Clinical trial, Randomized controlled trial and Refractory Multiple Myeloma.

He most often published in these fields:

  • Multiple myeloma (75.35%)
  • Internal medicine (69.25%)
  • Surgery (39.34%)

What were the highlights of his more recent work (between 2014-2020)?

  • Multiple myeloma (75.35%)
  • Internal medicine (69.25%)
  • Lenalidomide (38.09%)

In recent papers he was focusing on the following fields of study:

Antonio Palumbo spends much of his time researching Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Dexamethasone. His biological study spans a wide range of topics, including Gastroenterology, Clinical trial and Hazard ratio. His research on Internal medicine frequently connects to adjacent areas such as Surgery.

In his study, which falls under the umbrella issue of Lenalidomide, Prednisone is strongly linked to Melphalan. Within one scientific family, he focuses on topics pertaining to Elotuzumab under Oncology, and may sometimes address concerns connected to Isatuximab. When carried out as part of a general Dexamethasone research project, his work on Pomalidomide is frequently linked to work in In patient, therefore connecting diverse disciplines of study.

Between 2014 and 2020, his most popular works were:

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (818 citations)
  • Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma (771 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His primary scientific interests are in Internal medicine, Multiple myeloma, Lenalidomide, Surgery and Oncology. Internal medicine is frequently linked to Gastroenterology in his study. Antonio Palumbo studies Multiple myeloma, namely Bortezomib.

His Lenalidomide research incorporates themes from Melphalan, Autologous stem-cell transplantation, Progression-free survival and Phases of clinical research. His Surgery research is multidisciplinary, relying on both Elotuzumab and Adverse effect. His Oncology research is multidisciplinary, incorporating perspectives in Ixazomib, Clinical Oncology, Cancer Medicine, Placebo and Genetic counseling.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2229 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1148 Citations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)

1144 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)

1105 Citations

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci.
The Lancet (2010)

1052 Citations

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla.
The Lancet (2006)

1008 Citations

Targeting CD38 with daratumumab monotherapy in multiple myeloma

Henk M Lokhorst;Torben Plesner;Jacob P Laubach;Hareth Nahi.
The New England Journal of Medicine (2015)

916 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

866 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Antonio Palumbo

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 320

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 304

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 294

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 266

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 227

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 223

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 216

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 215

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 188

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 174

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 172

Sagar Lonial

Sagar Lonial

Emory University

Publications: 172

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 170

Maria-Victoria Mateos

Maria-Victoria Mateos

University of Salamanca

Publications: 165

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 156

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 155

Trending Scientists

Anibal T. de Almeida

Anibal T. de Almeida

University of Coimbra

Lin Zhuang

Lin Zhuang

Wuhan University

Markus Affolter

Markus Affolter

University of Basel

Joyce L. Hamlin

Joyce L. Hamlin

University of Virginia

Jane Elith

Jane Elith

University of Melbourne

Bruce D. Whitaker

Bruce D. Whitaker

United States Department of Agriculture

Claire L. Harris

Claire L. Harris

Newcastle University

Makoto Tachibana

Makoto Tachibana

Osaka University

A. Sarah Walker

A. Sarah Walker

University of Oxford

Zongbo Shi

Zongbo Shi

University of Birmingham

Danielle C. Cath

Danielle C. Cath

University Medical Center Groningen

Roger C.M. Ho

Roger C.M. Ho

National University of Singapore

Kathryn Bock

Kathryn Bock

University of Illinois at Urbana-Champaign

Harald Hampel

Harald Hampel

Université Paris Cité

David W. Oslin

David W. Oslin

University of Pennsylvania

Kyle S. Dawson

Kyle S. Dawson

University of Utah

Something went wrong. Please try again later.